BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Buc Calderon P, Beck R, Glorieux C. Targeting hsp90 family members: A strategy to improve cancer cell death. Biochem Pharmacol 2019;164:177-87. [PMID: 30981878 DOI: 10.1016/j.bcp.2019.04.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Zeng J, He SL, Li LJ, Wang C. Hsp90 up-regulates PD-L1 to promote HPV-positive cervical cancer via HER2/PI3K/AKT pathway. Mol Med 2021;27:130. [PMID: 34666670 DOI: 10.1186/s10020-021-00384-2] [Reference Citation Analysis]
2 León R, Soto-Delgado J, Montero E, Vargas M. Development of Computational Approaches with a Fragment-Based Drug Design Strategy: In Silico Hsp90 Inhibitors Discovery. Int J Mol Sci 2021;22:13226. [PMID: 34948022 DOI: 10.3390/ijms222413226] [Reference Citation Analysis]
3 Sundararajan R, Giri P, Madhivanan S, Ramesh A, Kishore NK, Manjunatha M, Camarillo IG. Cisplatin-based Electrochemotherapy Significantly Downregulates Key Heat Shock Proteins in MDA-MB-231-Human Triple-Negative Breast Cancer Cells. Appl Biochem Biotechnol 2021. [PMID: 34637110 DOI: 10.1007/s12010-021-03703-9] [Reference Citation Analysis]
4 Dent P, Booth L, Poklepovic A, Hancock JF. Signaling alterations caused by drugs and autophagy. Cell Signal 2019;64:109416. [PMID: 31520735 DOI: 10.1016/j.cellsig.2019.109416] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
5 Semkova S, Ivanova D, Nikolova B, Zlateva G, Bakalova R, Zhelev Z, Aoki I. Inhibition of ATP-synthase potentiates cytotoxicity of combination drug menadione/ascorbate in leukaemia lymphocytes. Biotechnology & Biotechnological Equipment 2021;35:1738-44. [DOI: 10.1080/13102818.2021.1996268] [Reference Citation Analysis]
6 Hall D. On the nature of the optimal form of the holdase-type chaperone stress response. FEBS Lett 2020;594:43-66. [PMID: 31432502 DOI: 10.1002/1873-3468.13580] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
7 Cheng CJ, Liu KX, Zhang M, Shen FK, Ye LL, Wu WB, Hou XT, Hao EW, Hou YY, Bai G. Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity. Acta Pharmacol Sin 2021. [PMID: 34326484 DOI: 10.1038/s41401-021-00737-x] [Reference Citation Analysis]
8 Tubita A, Lombardi Z, Tusa I, Dello Sbarba P, Rovida E. Beyond Kinase Activity: ERK5 Nucleo-Cytoplasmic Shuttling as a Novel Target for Anticancer Therapy. Int J Mol Sci 2020;21:E938. [PMID: 32023850 DOI: 10.3390/ijms21030938] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
9 Pugh KW, Zhang Z, Wang J, Xu X, Munthali V, Zuo A, Blagg BSJ. From Bacteria to Cancer: A Benzothiazole-Based DNA Gyrase B Inhibitor Redesigned for Hsp90 C-Terminal Inhibition. ACS Med Chem Lett 2020;11:1535-8. [PMID: 32832020 DOI: 10.1021/acsmedchemlett.0c00100] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Bakalova R, Semkova S, Ivanova D, Zhelev Z, Miller T, Takeshima T, Shibata S, Lazarova D, Aoki I, Higashi T. Selective Targeting of Cancerous Mitochondria and Suppression of Tumor Growth Using Redox-Active Treatment Adjuvant. Oxid Med Cell Longev 2020;2020:6212935. [PMID: 33204397 DOI: 10.1155/2020/6212935] [Reference Citation Analysis]